Minitabletted Pancreatin Pangrol 10 000 Iu and 25 000 Iu Efficacy and Safety in Patients with Cystic Fibrosis

The substitutive enzymatic therapy is vital in cystic fibrosis patients with pancreatic insufficiency. Usually patients are given enzymes at every meal. If it is necessary to replace one enzymatic remedy to another, the replacement should be done gradually (for 12-14 days). A comparative study of encapsulated enzyme preparations Creon 10 000 IU/25 000 IU and Pangrol 10 000 IU/25 000 IU safety, efficacy and tolerability was done in 20 patients with cystic fibrosis at the age of 11 months - 16 years. 13 people have got the doses in the calculation of the lipase up to 100 TU; and more than 100 TU - 7 people. Different drug doses effectiveness was determined according to faeces parameters and coprogram indicators. Numerical evaluation of the clinical efficacy and tolerability of both drugs was conducted through a questionnaire survey of patients and specialists. All patients completed the study. The effectiveness of the treatment according to coprogram was the same in both groups. In most cases, the process of transferring patients from Creon on Pangrol passed without the appearance of negative symptoms. It has been shown that encapsulated, mini-tablet pancreatin Pangrol well tolerated by patients. This allowed to 60 % of patients with cystic fibrosis change the treatment from Creon on Pangrol. Adverse events (10 %), detected in the process of transferring patients from one drug to another, were rare and short-term. The majority of physicians and patients prefer to continue therapy with Creon, according to their previous successful experience. Step-by-step scheme of replacing one enzymatic remedy on another is shown in this paper.